March 22, 2010 – The FDA’s Circulatory System Devices Panel last week unanimously recommended expanding the indication for cardiac resynchronization therapy defibrillators (CRT-Ds) to slow the progression of heart failure in patients with asymptomatic or mild heart failure (HF).
